We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00306176
First Posted: March 23, 2006
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Athens
Information provided by:
Aristotle University Of Thessaloniki
  Purpose
The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Condition Intervention Phase
Type II Diabetes Mellitus Drug: Rosiglitazone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Cardiovascular risk factors alterations

Estimated Enrollment: 100
Study Start Date: January 2005
Estimated Study Completion Date: October 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Type II diabetes mellitus
  • Poor glycemic control

Exclusion Criteria:

  • Heart failure
  • Renal disease
  • Liver disease
  • Cardiovascular event
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00306176


Locations
Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece, 54454
Sponsors and Collaborators
Aristotle University Of Thessaloniki
University of Athens
Investigators
Study Chair: Christos Liapis, PhD,MD University of Athens,Greece
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00306176     History of Changes
Other Study ID Numbers: 1975
First Submitted: March 22, 2006
First Posted: March 23, 2006
Last Update Posted: October 12, 2017
Last Verified: April 2007

Keywords provided by Aristotle University Of Thessaloniki:
rosiglitazone,exercise,cardiovascular risk factors

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs